Viamet Pharmaceuticals

Bright Angel Therapeutics

This biotechnology company develops small molecule inhibitors to treat patients with drug-resistant and life-threatening fungal infections.

F2G

This biopharmaceutical company develops novel antifungal therapies to treat patients with life-threatening rare and resistant fungal infections.

Pulmocide

This biopharmaceutical company develops inhaled antifungal medicines for patients with serious respiratory tract infections such as pulmonary aspergillosis.

SelectX Pharmaceuticals

This biopharmaceutical company develops small molecule antimicrobials and therapeutics for unmet medical needs using a genetic chemistry platform for patients with infectious diseases.

Elion Therapeutics

This biotechnology company develops antifungal medicines to prevent and treat life-threatening infections in immunocompromised patients, such as organ transplant and oncology recipients.

Melinta Therapeutics

This biopharmaceutical company develops and commercialises antibiotics and antifungals to treat drug-resistant infections in hospital and clinic settings.

Amplyx

This company develops antifungal and antiviral therapies for patients with compromised immune systems, such as cancer and transplant recipients.

MetalloBio

This company develops antimicrobial compounds and medical device coatings to combat antibiotic resistance for the pharmaceutical and healthcare sectors.